Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trilaciclib for Preventing Myelosuppression from Topoisomerase I Inhibitor ADCs
NCT07736001Phase 2Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Jul 2026
- Primary completion
- Jul 2029
- Countries
- 1
01
Overview
A Phase 2 trial of trilaciclib in myelosuppression, sponsored by Tianjin Medical University Cancer Institute and Hospital. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
trilaciclib
03
Conditions
myelosuppression
Beyond the preview
Go deeper on NCT07736001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07736001.